



Significantly Increased Risk of All-Cause Mortality Among Type 2 Diabetes Patients Living Alone

Liyao Fu^{1,2}, Ying Zhou^{1,2}, Jiaxing Sun², Zhenhua Xing², Yongjun Wang¹ and Shi Tai^{2*}

¹ Department of Blood Transfusion, The Second Xiangya Hospital of Central South University, Changsha, China, ² Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, Changsha, China

Background: There is a lack of studies evaluating the association between living status and subsequent outcomes in patients with type 2 diabetes (T2DM).

Objectives: This study aimed to assess the association between living alone and the risk of all-cause mortality in T2DM patients.

Methods: We performed a secondary analysis in patients with long-lasting T2DM from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. The primary outcome was all-cause mortality. Multivariable Cox proportional hazard models was used to analyze and compare the hazard ratios (HRs) in patients living alone and with one or more adults.

OPEN ACCESS

Edited by:

Redhwan Ahmed Al-Naggar, National University of Malaysia, Malaysia

Reviewed by:

Natalia Sharashkina, Pirogov Russian National Research Medical University, Russia Carlos Miguel Rios-González, National University of Caaguazú, Paraguay

> *Correspondence: Shi Tai taishi2017@csu.edu.cn

Specialty section:

This article was submitted to Family Medicine and Primary Care, a section of the journal Frontiers in Medicine

Received: 24 September 2021 Accepted: 04 January 2022 Published: 26 January 2022

Citation:

Fu L, Zhou Y, Sun J, Xing Z, Wang Y and Tai S (2022) Significantly Increased Risk of All-Cause Mortality Among Type 2 Diabetes Patients Living Alone. Front. Med. 9:782751. doi: 10.3389/fmed.2022.782751 **Results:** This study included 10,249 patients with T2DM. Of these, 2,078 (20.28%) were living alone and 8,171 (79.72%) lived with one or more adults. Over a median total follow-up of 8.8 years, 1,958 patients developed the primary endpoint. The all-cause mortality rates in patients living alone or living with one or more adults were 23.24 and 18.05%, respectively. Cox proportional hazard analysis showed that T2DM patients living alone had significantly higher rate of all-cause mortality than those living with others (HR, 1.34; 95% confidence interval [CI], 1.20–1.48; p < 0.001). After multivariable adjustment, living alone was an independent risk factor for all-cause mortality in patients with T2DM (adjusted HR, 1.27; 95% CI, 1.14–1.41; p < 0.001). Furthermore, the risks of both congestive heart failure (CHF) and fatal coronary heart disease (CHD) among 4,050 propensity score-matched patients were higher for patients living alone (respectively HR, 1.37; 95% CI, 1.08–1.74; p = 0.010; and HR, 1.16; 95% CI, 1.00–1.34; p = 0.047).

Conclusions: The risk of all-cause mortality was significantly higher in T2DM patients living alone than in those living with one or more adults.

Keywords: type 2 diabetes, living alone, all-cause mortality, hazard ratio, congestive heart failure (CHF), coronary heart disease (CAD)

INTRODUCTION

The number of individuals living alone is increasing among older people in developing and developed countries, and this is considered an important demographic and social change (1). In 2017, 33.6% of the households in the European Union and around 40% of those in Nordic countries (except Iceland) consisted of one individual living alone (2). Complex reasons explain this trend, such as, for instance, trends

1

toward longevity, high divorce rates, high rates of widowhood, and low rates of intergenerational co-residence (3). Living alone may cause social isolation and feelings of loneliness and depression, especially when individuals perceive that their social needs are not met. The influence of social isolation on mortality and morbidity has been established among the traditional clinical risk factors (2, 4, 5). Meanwhile, loneliness and depression can negatively impact health and survival. Meta-analytic evidence demonstrates that loneliness is a predictor of all-cause mortality, showing that lonely people have a 22% higher risk of death than do non-lonely people (1). Moreover, living alone also entails a higher cost of living and may increase the economic burden of low-income people (6). Thus, living alone arises as a new concern with aging in patients with chronic non-communicable diseases.

Previous studies have demonstrated a significant association between living alone and mortality among older people (7, 8). The causal pathways connecting living alone with mortality are multifactorial. The social networks of individuals living alone tend to shrink, and these individuals are also likely to be in poorer health. Meanwhile, patients living alone have an increasing trend toward poor health behaviors (5, 9), and are also more likely to experience unmet care needs (10). In addition, several studies found that single living increased worse outcomes post heart attack or myocardial infarction (11, 12). More recently, our previous study demonstrated living alone is an independent risk factor for 1-year all-mortality in acute coronary syndrome patients \geq 75 years of age (13). Given type 2 diabetes mellitus (T2DM) has been associated with the onset of atherosclerotic cardiovascular disease among older patients, often presenting as coronary heart disease (CHD), cerebrovascular disease, and cardiovascular death of atherosclerotic origin in patients (14), subsequently promoting premature aging. Therefore, there is an urgent need for cardiovascular events prevention in diabetic individuals. To achieve this goal, it is necessary to identify specific high-risk factors affecting the prognosis of T2DM in primary care.

The percentage of T2DM patients living alone has been reported to be \sim 7–15% (15). To date, no study has prospectively assessed the association between living alone and incident T2DM, although cross-sectional studies have investigated living alone as a risk factor for T2DM (16, 17). As individuals with T2DM tend to live for a long time with advanced comorbidities, it is significant for public health to determine whether living status is independently associated with poor clinical outcomes. However, previous studies have exclusively focused on the relationship between living alone and the incidence of T2DM. Therefore, the present study examined the association between living alone and clinical outcomes in T2DM. We used the data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study (18) and the ACCORD Follow-On Study (ACCORDION) (19) to assess the association between living arrangements and all-cause mortality in patients with T2DM.

METHODS

Study Participants and Data Collection

We performed a *post-hoc* analysis of the data from the ACCORD trial (ClinicalTrials.gov number, NCT00000620; data obtained

from the Biologic Specimen and Data Repository Information Coordinating Center, National Heart, Lung and Blood Institute, U.S. Department of Health and Human Services). The rationale and design of the ACCORD trial have been described previously (20). Briefly, the ACCORD trial was a 2 \times 2 factorial trial managed at 77 clinical sites in the United States and Canada, which recruited 10,251 T2DM patients aged between 40 and 79 years with glycosylated hemoglobin (HbA1c) concentration of 7.5% or more. The trial was designed to test whether the intensified control of blood glucose, blood pressure, and lipids could reduce the incidence of cardiovascular disease (CVD) in patients with T2DM. The included patients had a history of CVD, indicated by anatomical evidence of significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least two risk factors for cardiovascular diseases. Intensive control of blood pressure and lipids did not reduce CVD. However, intensive glycemic intervention was discontinued after a mean follow-up of 3.7 years because of the increased mortality in the intensive glycemic control group, and all participants were transitioned to standard glycemic control intervention. The ACCORD closeout visits were completed in June of 2009. Follow-up continued for the remaining participants in the ACCORDION trial, with a total follow-up period of 8.8 years. Ethics approval and consent to participate were not applicable.

Exposure Variables

We excluded participants whose living arrangement baseline data were missing (n = 2). This resulted in a final sample of 10,249 participants for the analysis of the association between baseline living status and clinical outcomes. Living arrangement status at baseline was documented as either living alone or living with one or more adults. Further information collected at baseline included demographics, medical history, previous cardiovascular events, mental health, laboratory values (e.g., fasting blood glucose, HbA1c, estimated glomerular filtration rate (eGFR), total cholesterol, and triglycerides), and current chronic drug regimen.

Study Outcomes and Definitions

The primary outcome of this study was all-cause mortality. Secondary endpoints were cardiovascular mortality, non-fatal stroke, non-fatal myocardial infarction (MI), congestive heart failure (CHF), and fatal coronary heart disease (CHD). Patients were followed up every 2–4 months through phone interviews or visits at the outpatient clinic. At 4-month intervals, the relevant medical information was collected. The study outcomes were classified by the Working Group of the Morbidity and Mortality subcommittee.

Statistical Analysis

Qualitative demographic data are presented as numbers (percentages), and baseline characteristics of patients living alone and living with others were compared using the chi-square test. Quantitative data are presented as mean \pm SD, and the Student's *t*-test was used to compare baseline characteristics. Kaplan-Meier survival curves were used to analyze primary and secondary outcomes in patients living alone or living

with others, and the differences between groups in cumulative incidence curves were compared using the log-rank test. A Cox proportional hazards regression model was used to calculate the hazard ratio (HR) and 95% confidence intervals (CIs) for the primary and secondary outcomes in the comparisons of patients living alone or living with others. The proportional hazards assumption was examined using Schoenfeld residuals. Three multivariable models with progressive degrees of adjustment were used to adjust for potential confounders of the study outcomes. Model 1 was adjusted for age, sex, race, body mass index (BMI), previous cardiovascular events, education level, systolic blood pressure (SBP), diastolic blood pressure (DBP), and smoking status. Model 2 was further adjusted for other clinical variables, including duration of diabetes, eGFR, HbA1c, total plasma cholesterol, plasma high-density lipoprotein cholesterol (HDL-C), plasma low-density lipoprotein cholesterol (LDL-C), and depression status. Model 3 was further adjusted for the use of statins, biguanide, aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), and insulin.

The primary and secondary outcomes in propensity scorematched patients with different living statuses were determined using Cox proportional hazard analysis. We used 1:1 nearestneighbor matching without replacement to match all the baseline characteristics. The propensity score was calculated using a logistic regression model. Standardized differences <0.10 between propensity score-matched patients were considered negligible. The effect of living alone in patients with T2DM was further analyzed according to subgroup analysis: sex (male or female), age (<60 or \geq 60 years), race (white or non-white), CVD (CVD history or no CVD history), HbAc1 level (<8.0% or \geq 8.0%), depression (depression or non-depression), smoking (no history of smoking or history of smoking), and use of insulin or statins. Statistical significance was set at P < 0.05. All statistical analyses were performed using the Statistical Product and Service Solution version 25 (IBM, Armonk, NY, USA).

RESULTS

Baseline Characteristics According to Living Arrangement

A total of 10,249 patients were eligible for inclusion in this analysis, including 2,078 documented as living alone (20.28%) and 8,171 (79.72%) living with one or more adults. Patients enrolled in the current study were 62.76 ± 6.64 years old on average. The baseline characteristics are shown in **Table 1**. Participants living alone were older and more often female and white. They had higher BMI, heart rate (HR), HbAc1, total cholesterol, LDL-C, urinary creatinine, urinary albumin, and lower levels of eGFR than those living with one or more adults (all P < 0.001). Likewise, participants living alone had more frequent smoking history, higher prevalence of CVD, prior hospitalization for heart failure (HF), depression, and CHF, were more prone to taking metformin and insulin, and less prone to take statins than patients living with one or more adults (all P < 0.001).

Association Between Living Arrangement and All-Cause Mortality

During a median follow-up of 8.8 years, 1,958 patients (19.10%) developed all-cause mortality. As Table 2 shows, the incidence of all-cause mortality was higher in patients who lived alone than in those living with other adults (483 [23.24%] vs. 1,475 [18.05%], P = 0.001). In the unadjusted model, patients living alone had a higher risk of all-cause mortality (HR, 1.34; 95% CI, 1.20-1.48; P < 0.001) and non-fatal stroke (HR, 1.26; 95% CI, 1.02-1.56; P = 0.030) than those living with one or more adults. There was no difference in the rates of cardiovascular mortality, non-fatal MI, CHF, or CHD. Kaplan-Meier survival curves and cumulative event rates for the primary and secondary outcomes in patients with different living statuses are shown in Figure 1 and Table 2, respectively. In the multivariable model, there remained statistically significant differences in all-cause mortality (model 1: adjusted HR, 1.31; 95% CI, 1.18-1.46; P < 0.001; model 2: adjusted HR, 1.27; 95% CI, 1.14–1.41; *P* < 0.001; model 3: adjusted HR, 1.27; 95% CI, 1.14–1.41; *P* < 0.001). There were no differences between patients living alone and those living with one or more adults in cardiovascular mortality, non-fatal MI, non-fatal stroke, CHF, and CHD.

We used propensity score matching as a sensitivity analysis to verify the association between living alone and the risk of primary and secondary outcomes in patients with T2DM. Among the propensity score-matched patients (n=4,050), the risk of all-cause mortality (HR, 1.34; 95% CI, 1.17–1.53; P < 0.001), CHF (HR, 1.37; 95% CI, 1.08–1.74; P = 0.010), and CHD (HR, 1.16; 95% CI, 1.00–1.34; P = 0.047) were significantly higher in patients living alone than in those living with one or more adults, whereas there were no differences in the risk of adverse CV events, cardiovascular mortality, non-fatal stroke, and non-fatal MI. Kaplan-Meier survival curves and cumulative event rates for primary and secondary outcomes are shown in **Figure 2**.

Association Between Living Arrangements and All-Cause Mortality in Different Subgroups

Interaction and stratified analyses were performed to evaluate the association between living arrangements and all-cause mortality in the different subgroups (**Figure 3**). We did not find interactions among age, sex, previous history of CVD, depression status, smoking history, HbA1C, use of insulin, or use of statins, suggesting that the results of different subgroups are consistent and reliable.

DISCUSSION

In this study, we found an association between living alone and mortality in T2DM. Unadjusted analysis showed that people living alone had a higher incidence of all-cause mortality (the primary endpoint) and non-fatal stroke. However, there were no differences in CV mortality, non-fatal MI, CHF, or CHD between the two groups. Importantly, living alone in patients with T2DM was independently associated with an increased risk of all-cause mortality after adjusting for confounding variables. TABLE 1 | Characteristics of patients with different living status.

No ($\mu = 8, 171$) Yes ($\mu = 2.078$) Age (year, mean \pm SD) 62.79 ± 6.64 62.64 ± 6.68 63.09 ± 6.79 <0.001 Sex no. (9)	Variable	All (n = 10,249)	Living alone		P-value
$\begin{array}{c} \mbox{pc}({\rm sort;} {\rm mean}\pm 50) & 62.76\pm 6.64 & 62.54\pm 6.58 & 63.68\pm 6.73 & <0.001 \\ \mbox{Sec no.}(6) & & & & & & & & & & & & & & & & & & &$			No (<i>n</i> = 8,171)	Yes (<i>n</i> = 2,078)	
Sector (%) Sector (%) C269(6)14.6%) C264(6)4.6%) C760(6).7% C700(6).7% Finalo 0.000 (78.0%) C244(6)4.6%) 1.102 (20.0%) C707(60.3.6%) C246(6)4.6%) C246	Age (year; mean \pm SD)	62.76 ± 6.64	62.54 ± 6.58	63.66 ± 6.79	<0.001
Maie 5.229 (61.46%) 5.232 (62.16%) 17.02 (63.03%) 0.01 Fermale 3.050 (38.56%) 2.848 (94.85%) 11.02 (63.03%) 0.01 Minte 0.302 (62.37%) 5.177 (63.30%) 12.15 (68.47%) 0.01 Modian duration of hipbering (war; mean ± 5D) 10.89 ± 7.60 10.77 ± 7.52 10.83 ± 7.89 0.497 Median duration of hipbering (war; mean ± 5D) 10.32 ± 8.8 10.12 ± 9.46 10.07 ± 110.09 0.049 Previous cardioxesular events no. (%) 3.008 (35.20%) 2.942 (98.01%) 0.88 (42.73%) 0.049 Smoking 5.955 (80.0%) 4.765 (63.32%) 1.1016 / 7.27%) 0.835 Smoking 5.955 (80.0%) 4.765 (63.32%) 1.0106 / 7.27%) 0.835 Smoking 1.521 (14.84%) 1.219 (14.92%) 302 (14.53%) 0.835 Smoking 1.521 (14.84%) 1.219 (14.92%) 302 (14.53%) 0.216 Calega dargee or higher 2.961 (25.96%) 2.162 (26.32%) 7.04 (33.83%) 0.218 Calega dargee or higher 2.961 (25.96%) 2.126 (26.02%) 3036 (47.2%)	Sex no. (%)				
Fermine 3,660 (36,54%) 2,448 (34,85%) 1,102 (53,03%) Race no. (%)	Male	6,299 (61.46%)	5,323 (65.15%)	976(46.97%)	< 0.001
Race no. (%) 5.077 (83.36%) 5.1216 (86.47%) 5.0301 White 3.857 (67.33%) 2.204 (20.61%) 0.030 ± 7.80 0.040 Moden duration of hipertension (sear, mean ± 50) 1.080 ± 7.80 1.077 ± 7.52 1.003 ± 7.80 0.0409 Moden duration of hypertension (sear, mean ± 50) 5.06 ± 5.70 5.54 ± 5.66 5.96 ± 5.70 0.0409 Previous cardiovescular events nc. (%) 3.060 (55.20%) 2.042 (80.01%) 0.061 (7.100) 0.0409 Stranding 2.955 (82.0%) 3.406 (41.68%) 888 (62.73%) 0.065 Stranding 2.955 (82.0%) 3.406 (41.68%) 888 (62.73%) 0.066 Stranding 2.956 (82.0%) 3.050 (61.65%) 0.066 0.067 Stranding 2.956 (82.0%) 2.169 (85.5%) 0.067 0.066 Stranding 2.957 (82.0%) 2.056 (82.4%) 7.04 (33.39%) 0.067 Stranding 2.956 (82.9%) 2.169 (85.5%) 0.067 0.067 Stranding aduate 1.707 (12.366 (11.1%) 1.707 (12.368 (11.1%) 0.061 Stranding aduate	Female	3,950 (38.54%)	2,848 (34.85%)	1,102 (53.03%)	
While 6,332 (02.37%) 5,17 (03.35%) 1,216 (68.47%) Non-white 3,857 (67.63%) 2,994 (66.64%) 4803 (41.53%) Median duration of hyperiferionia (year; mean ± 50) 5.66 ± 5.70 5.65 ± 5.66 5.66 ± 5.76 Median duration of hyperiferionia (year; mean ± 50) 3.60 (65.20%) 2.942 (66.11%) 0.66 (20.0%) 0.049 Previous acridovascular worts no. (%) 3.60 (61.65%) 4.705 (58.32%) 1.100 (72.7%) 0.875 Smoking 5.95 (56.5%) 4.705 (58.32%) 1.100 (72.7%) 0.665 High school graduate 5.721 (14.84%) 2.169 (26.55%) 5.85 (25.7%) 0.665 High school graduate 2.704 (26.38%) 2.169 (26.55%) 5.85 (25.7%) 0.665 Some collage or technical school 3.367 (62.7%) 2.683 (82.47%) 7.04 (38.8%) 0.216 Some collage or technical school 3.367 (82.7%) 2.685 (82.7%) 0.800 0.809 Previous heart failure no. (%) 494 (4.82%) 386 (47.2%) 7.04 (38.8%) 0.216 Some collage or technical school 3.387 (82.7%) 1.085 (32.7%) 0.000	Race no. (%)				< 0.001
Non-whie 3,857 (J7.63%) 2,940 (46,64%) 863 (41,63%) Madian duration of thyperipiderma (year; mean ± 5D) 10,80 ± 7,80 10,77 ± 7,52 10,33 ± 7,89 0.407 Madian duration of thyperipiderma (year; mean ± 5D) 10,23 ± 9,58 10,12 ± 9,45 10,67 ± 10,09 0.049 Previous cardiovascular werts no. (%) 3,608 (55,20%) 2,942 (80,01%) 686 (82,20%) 0.001 Smoking status no. (%) 3,608 (41,68%) 888 (42,73%) 0.407 Smoking status no. (%) 3,608 (76,83,2%) 1,190 (77,27%) 0.667 Smoking status no. (%) 3,905 (76,27%) 2,663 (26,37%) 0.467 Smoking status no. (%) 2,661 (26,38%) 2,169 (26,55%) 535 (25,7%) 0.467 Smoking status no. (%) 2,661 (26,98%) 2,168 (26,55%) 535 (25,7%) 0.469 Calega degree or higher 2,661 (25,98%) 2,168 (26,55%) 535 (25,7%) 0.469 Depression no. (%) 2,419 (23,60%) 1,767 (19,9%) 622 (25,7%) 0.669 Depression no. (%) 2,419 (23,60%) 1,762 (19,9%) 622 (25,7%) 0.600 <tr< td=""><td>White</td><td>6,392 (62.37%)</td><td>5,177 (63.35%)</td><td>1,215 (58.47%)</td><td></td></tr<>	White	6,392 (62.37%)	5,177 (63.35%)	1,215 (58.47%)	
Median duration of diabetes (year; mean ± SD) 10.80 ± 7.60 10.77 ± 7.52 10.83 ± 7.89 0.407 Median duration of hyperfishio (year; mean ± SD) 0.59 ± 5.80 10.12 ± 9.45 10.67 ± 7.52 10.67 ± 7.50 0.049 Previous cardiovascular ovents no. (%) 3.608 (55.05%) 2.942 (66.01%) 666 (52.05%) 0.001 Smoking status no. (%) 3.406 (41.68%) 868 (42.75%) 0.875 Smoking status no. (%) 3.406 (41.68%) 868 (42.75%) 0.665 Smoking status no. (%) 3.406 (41.68%) 1.190 (57.27%) Education no. (%) Education no. (%) 1.219 (14.45%) 302 (14.55%) 0.665 Some college of graduate 2.704 (26.38%) 2.168 (62.4%) 556 (25.7%) 0.467 Some college of graduate 2.704 (26.38%) 2.126 (66.02%) 555 (25.7%) 0.669 College degree or higher 2.661 (25.6%) 2.126 (26.02%) 555 (25.7%) 0.669 College degree or higher 2.661 (25.6%) 2.212 (26.62%) 555 (25.7%) 0.669 Depression no. (%) 2.419 (23.60%) 1.737 (19.6%) 622 (25.7%)	Non-white	3,857 (37.63%)	2,994 (36.64%)	863 (41.53%)	
Median duration of hyperlipidemia (year; mean ± SD) 5.96 ± 5.70 5.95 ± 5.66 5.96 ± 5.86 0.985 Median duration of hyperlipidemia (year; mean ± SD) 10.23 ± 9.58 10.12 ± 9.45 10.67 ± 10.09 0.049 Previous cardiovascular events no. (%) 3.080 (61.08%) 2.942 (36.01%) 686 (42.73%) 5.037 Smoking 5.96 (56.0%) 4.765 (58.32%) 1,190 (57.27%) 0.665 High school graduate 1.521 (14.84%) 1.219 (14.92%) 302 (14.53%) 0.665 High school graduate 2.061 (25.05%) 355 (52.75%) 0.467 3.085 0.216 0.039 Some college or technical school 3.357 (32.75%) 2.653 (32.47%) 704 (33.88%) 0.216 College degree or higher 2.661 (25.08%) 2.166 (26.2%) 305 (25.75%) 0.000 Deprevals heart lature no. (%) 2.419 (23.60%) 1.797 (21.99%) 622 (25.71%) 0.001 Set prevals heart lature no. (%) 2.419 (23.60%) 1.797 (21.99%) 622 (25.71%) 0.000 Deprevals heart lature no. (%) 2.419 (23.60%) 1.797 (21.99%) 622 (25.71%) 0.001	Median duration of diabetes (year; mean \pm SD)	10.80 ± 7.60	10.77 ± 7.52	10.93 ± 7.89	0.407
Median duration of hypertension (year; mean ± SD) 10.23 ± 9.83 10.12 ± 9.45 10.67 ± 10.03 0.049 Previous cardiovascular events n.e. (%) 3.008 (65.20%) 2.942 (86.01%) 666 (82.05%) 0.017 Smoking status o. (%) 3.406 (41.68%) 888 (42.73%) 1.190 (57.27%) Smoking status o. (%) 3.656 (85.05%) 4.765 (85.32%) 1.190 (57.27%) 0.666 Education on. (%) 1.219 (14.92%) 302 (14.53%) 0.666 Some college or technical school graduate 1.521 (14.84%) 1.219 (26.62%) 535 (25.75%) 0.467 Some college or technical school 3.257 (32.75%) 2.663 (32.47%) 704 (33.88%) 0.216 College deger or higher 2.661 (25.96%) 2.126 (26.02%) 535 (25.75%) 0.809 Previous heart falture no. (%) 494 (4.82%) 396 (4.72%) 108 (55.62 +75%) 0.809 Degression no. (%) 7.49 ± 10.58 7.49 ± 10.58 7.49 ± 10.58 7.49 ± 10.58 7.49 ± 10.58 7.403 ± 10.96 0.822 Def (mmHg, mean ± SD) 7.49 ± 10.58 7.49 ± 10.58 7.40 ± 3.3 ± 10.45 3.46 ± 1.07 <td< td=""><td>Median duration of hyperlipidemia (year; mean \pm SD)</td><td>5.96 ± 5.70</td><td>5.95 ± 5.66</td><td>5.96 ± 5.86</td><td>0.985</td></td<>	Median duration of hyperlipidemia (year; mean \pm SD)	5.96 ± 5.70	5.95 ± 5.66	5.96 ± 5.86	0.985
Previous cardiovascular events no. (%) 3,608 (35.20%) 2,942 (26.01%) 666 (32.05%) 0.001 Smoking status no. (%)	Median duration of hypertension (year; mean \pm SD)	10.23 ± 9.58	10.12 ± 9.45	10.67 ± 10.09	0.049
Smoking status no. (%) 4.294 (41.09%) 3.406 (41.68%) 6.88 (42.73%) No smoking 5.965 (68.0%) 4.765 (68.32%) 1.100 (67.27%) Education no. (%) 2.704 (26.38%) 2.219 (14.92%) 3.02 (14.53%) 0.665 Some collage or technical school 3.357 (22.75%) 2.653 (32.47%) 7.04 (33.88%) 0.216 College degree or higher 2.661 (25.69%) 2.128 (26.02%) 5.35 (25.75%) 0.809 Previous heart falure no. (%) 4.94 (4.82%) 3.86 (4.72%) 0.80 (22.25.71%) 0.000 Bopression no. (%) 2.419 (23.60%) 1.77 (21.99%) 622 (25.71%) 0.000 Bopression no. (%) 2.419 (23.60%) 1.77 (21.99%) 622 (25.71%) 0.000 SBP (mmHg, mean ± SD) 7.86 ± 11.82 72.34 ± 11.64 7.38 ± 12.43 <0.001	Previous cardiovascular events no. (%)	3,608 (35.20%)	2,942 (36.01%)	666 (32.05%)	0.001
No smoking 4,294 (41,09%) 3,406 (41,68%) 888 (42,73%) Smoking 5,956 (86.0%) 4,765 (56.32%) 1,721 (14,53%) 0.665 Education no. (%) 12.91 (14,92%) 302 (14,53%) 0.665 Some logge or technical school 3,357 (32,75%) 2,453 (26,02%) 535 (25,75%) 0.467 Some college or technical school 3,357 (32,75%) 2,653 (26,02%) 535 (25,75%) 0.809 Previous heart failure no. (%) 2,461 (25,08%) 1,797 (21,99%) 622 (25,71%) 0.000 Bepression no. (%) 2,419 (23,60%) 1,797 (21,99%) 622 (25,71%) 0.000 Bepression no. (%) 2,419 (23,60%) 1,797 (21,99%) 622 (25,71%) 0.000 Bepression no. (%) 2,419 (23,60%) 1,797 (21,99%) 622 (25,71%) 0.000 Bepression no. (%) 2,419 (23,60%) 1,797 (21,99%) 622 (25,71%) 0.000 Bepression no. (%) 2,419 (23,60%) 1,787 (21,99%) 622 (52,71%) 0.000 Bepression no. (%) 2,419 (23,60%) 1,747 (21,99%) 622 (52,71%) 0.001	Smoking status no. (%)				0.387
Smoking 5,955 (58.0%) 4,765 (58.3%) 1,190 (57.27%) Education no. (%) Less than high school graduate 1,521 (14,84%) 1,219 (14,92%) 302 (14.53%) 0,665 High school graduate 2,704 (26,38%) 2,109 (26,55%) 535 (25,75%) 0,467 Some college or technical school 3,357 (22,75%) 2,663 (24,75%) 2,663 (24,75%) 108 (5,05%) 0,309 Depression no. (%) 2,419 (23,60%) 1,797 (21,99%) 622 (25,71%) 0,000 Heart rate (mean ± 5D) 72,85 ± 11.82 72,34 ± 11.64 73,88 ± 12,43 -0,001 SDP (mmHg, mean ± SD) 32,22 ± 5,42 30,10 ± 5,38 32,88 ± 5,57 -0,001 SPG (mg/cL, mean ± SD) 32,22 ± 5,42 30,10 ± 5,38 34,84 ± 1,03 0,832 SPG (mg/cL, mean ± SD) 10,65 ± 27,15 91,46 ± 27,50 83,34 ± 6,57 -0,001 FPG (mg/cL, mean ± SD) 175,19 ± 56,18 174,7 ± 55,79 177,12 ± 57,66 0,007 FPG (mg/cL, mean ± SD) 183,29 ± 41,85 182,45 ± 41,69 186,56 ± 42,50 0,001 FPG (mg/cL, mean	No smoking	4,294 (41.09%)	3,406 (41.68%)	888 (42.73%)	
Education no. (%) 1.521 (14.84%) 1.219 (14.92%) 302 (14.53%) 0.686 High school graduate 2,704 (26.38%) 2,169 (26.55%) 535 (25.75%) 0.467 Some college or technical school 3,357 (32.75%) 2,663 (32.47%) 704 (33.85%) 0.208 College degree or higher 2,661 (25.96%) 2,126 (26.02%) 535 (25.75%) 0.809 Previous heart failure no. (%) 494 (48.2%) 386 (47.2%) 108 (50.2%) 0.000 Heart rate (mean ± 5D) 72.66 ± 11.82 72.43 ± 11.64 73.88 ± 12.43 <0.001	Smoking	5,955 (58.0%)	4,765 (58.32%)	1,190 (57.27%)	
Less than high school graduate 1,521 (14,84%) 1,219 (14,92%) 302 (14,53%) 0,665 High school graduate 2,704 (26,38%) 2,169 (26,55%) 535 (25,75%) 0,467 Some college or technical school 3,357 (32,75%) 2,653 (32,47%) 704 (33,88%) 0,216 College degre or higher 2,661 (25,69%) 2,126 (26,02%) 536 (25,75%) 0,309 Pervious heart failure no. (%) 494 (4,82%) 386 (4,72%) 108 (5,02%) 0,309 Depression no. (%) 2,419 (23,60%) 1,797 (21,94%) 622 (25,71%) 0,000 Heart rate (mean ± SD) 72,65 ±11,82 72,34 ±11,64 73,88 ±12,43 -0,001 SBP (nmHg, mean ± SD) 74,89 ±10,58 74,89 ±10,58 74,83 ±10,96 0,822 DM (mean ± SD) 22,25 ±42 30,10 ±5,38 32,68 ±5,57 -0,001 Gycated hemoglobin (%, mean ± SD) 175,19 ±56,18 174,75 ±57,9 177,71 ± 57,66 0,007 Perdisult (mydL, mean ± SD) 175,19 ±56,18 174,74 ±57,9 177,71 ± 57,66 0,001 Potassium (mydL, mean ± SD) 193,29 ±41,85 182,45	Education no. (%)				
High school graduate 2,704 (26.38%) 2,169 (26.55%) 535 (25.75%) 0.467 Some college or technical school 3,357 (32.76%) 2,663 (22.47%) 704 (33.88%) 0.216 College degree or higher 2,661 (25.96%) 2,126 (26.02%) 535 (25.75%) 0.809 Deprevious heart failure no. (%) 449 (4.82%) 386 (4.72%) 108 (6.02%) 0.000 Heart rate (mean ± SD) 72.65 ± 11.82 72.34 ± 11.64 73.88 ± 12.43 <0.001	Less than high school graduate	1,521 (14.84%)	1,219 (14.92%)	302 (14.53%)	0.665
Some college or technical school 3,357 (32.75%) 2,653 (32.47%) 704 (33.88%) 0.216 College degree or higher 2,661 (25.96%) 2,126 (26.02%) 555 (25.75%) 0.809 Previous heart failure no. (%) 494 (4.82%) 386 (4.72%) 108 (5.02%) 0.309 Depression no. (%) 2,419 (23.60%) 1,797 (21.99%) 622 (25.71%) 0.000 Heart rate (mean ± SD) 72.65 ± 11.82 72.34 ± 11.64 73.88 ± 12.43 <0.001	High school graduate	2,704 (26.38%)	2,169 (26.55%)	535 (25.75%)	0.467
College degree or higher 2,661 (25.96%) 2,126 (26.02%) 535 (25.75%) 0.809 Previous heart failure no. (%) 494 (4.82%) 386 (4.72%) 108 (5.02%) 0.369 Depression no. (%) 2,419 (23.60%) 1,797 (21.99%) 622 (25.71%) 0.000 Heart rate (mean ± SD) 72.65 ± 11.82 72.34 ± 11.64 73.88 ± 12.43 <.0001	Some college or technical school	3,357 (32.75%)	2,653 (32.47%)	704 (33.88%)	0.216
Previous heart falure no. (%) 494 (4.82%) 386 (4.72%) 108 (5.02%) 0.369 Depression no. (%) 2.419 (23.60%) 1.797 (21.99%) 622 (25.71%) 0.000 Heart rate (mean ± SD) 72.65 ± 11.82 72.44 ± 11.64 73.88 ± 12.43 <-0.001	College degree or higher	2,661 (25.96%)	2,126 (26.02%)	535 (25.75%)	0.809
Depression no. %) 2,419 (23.60%) 1,797 (21.99%) 622 (25.71%) 0.000 Heart rate (mean ± SD) 72.65 ± 11.82 72.34 ± 11.64 73.88 ± 12.43 <0.001	Previous heart failure no. (%)	494 (4.82%)	386 (4.72%)	108 (5.02%)	0.369
Hear rate (mean \pm SD)72.65 \pm 11.8272.34 \pm 11.6473.88 \pm 12.43<0.001SBP (mmHg, mean \pm SD)136.36 \pm 17.11136.31 \pm 16.97136.66 \pm 17.660.564DBP (mmHg, mean \pm SD)74.99 \pm 10.5874.89 \pm 10.5874.83 \pm 10.960.322SMI (mean \pm SD)32.22 \pm 5.4230.10 \pm 5.3832.68 \pm 5.57<0.001	Depression no. (%)	2,419 (23.60%)	1,797 (21.99%)	622 (25.71%)	0.000
SBP (mmHg, mean \pm SD)136.36 \pm 17.11136.31 \pm 16.97136.56 \pm 17.660.664DBP (mmHg, mean \pm SD)74.89 \pm 10.5874.89 \pm 10.5874.83 \pm 10.960.822BMI (mean \pm SD)32.22 \pm 5.4230.10 \pm 5.3832.68 \pm 5.57<0.001	Heart rate (mean \pm SD)	72.65 ± 11.82	72.34 ± 11.64	73.88 ± 12.43	<0.001
DBP (mmHg, mean ± SD) 74.89 ± 10.58 74.89 ± 10.58 74.89 ± 10.58 74.83 ± 10.96 0.822 BMI (mean ± SD) 32.22 ± 5.42 30.10 ± 5.38 32.68 ± 5.57 <0.001	SBP (mmHg, mean \pm SD)	136.36 ± 17.11	136.31 ± 16.97	136.56 ± 17.66	0.564
BMI (mean \pm SD) 32.22 ± 5.42 30.10 ± 5.38 32.08 ± 5.57 <0.001 Glycated hemoglobin (%, mean \pm SD) 8.30 ± 1.06 8.2 ± 1.05 8.4 ± 1.07 0.011 eGFR (mL/min, mean \pm SD) 91.05 ± 27.15 91.48 ± 27.50 89.36 ± 56.70 0.001 FPG (mg/dL, mean \pm SD) 175.19 ± 56.18 174.7 ± 55.79 177.12 ± 57.66 0.087 ALT (UL, mean \pm SD) 27.58 ± 16.19 27.97 ± 16.68 26.05 ± 13.98 <0.001 Potassium (mg/dL, mean \pm SD) 4.48 ± 0.47 4.48 ± 0.47 4.46 ± 0.49 0.194 Cholesterol (mg/dL, mean \pm SD) 193.29 ± 41.85 182.45 ± 41.69 186.56 ± 42.50 0.001 Tiglyceride (mg/dL, mean \pm SD) 194.89 ± 33.93 104.37 ± 33.67 106.97 ± 34.79 0.002 Low-density lipoprotein (mg/dL, mean \pm SD) 0.91 ± 0.23 0.91 ± 0.23 0.91 ± 0.24 0.883 Urinary creatinine (mg/dL, mean \pm SD) 102.7 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 102.7 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 102.7 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 102.7 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 102.7 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 10.27 ± 36.60 9.77 ± 34.75 12.23 ± 42	DBP (mmHg, mean \pm SD)	74.89 ± 10.58	74.89 ± 10.58	74.83 ± 10.96	0.822
Glycated hemoglobin (%, mean \pm SD)8.30 \pm 1.068.2 \pm 1.058.4 \pm 1.070.011eGFR (mL/min, mean \pm SD)91.05 \pm 27.1591.48 \pm 27.5089.36 \pm 56.700.001FPG (mg/dL, mean \pm SD)175.19 \pm 56.18174.7 \pm 55.79177.12 \pm 57.660.087ALT (U/L, mean \pm SD)27.58 \pm 16.1927.97 \pm 16.6826.05 \pm 13.98<0.001	BMI (mean \pm SD)	32.22 ± 5.42	30.10 ± 5.38	32.68 ± 5.57	<0.001
eGFR (mL/min, mean ± SD)91.05 ± 27.1591.48 ± 27.5089.36 ± 56.700.001FPG (mg/dL, mean ± SD)175.19 ± 56.18174.7 ± 55.79177.12 ± 57.660.087ALT (U/L, mean ± SD)27.58 ± 16.1927.97 ± 16.6826.05 ± 13.98<0.001	Glycated hemoglobin (%, mean \pm SD)	8.30 ± 1.06	8.2 ± 1.05	8.4 ± 1.07	0.011
FPG (mg/dL, mean \pm SD)175.19 \pm 56.18174.7 \pm 55.79177.12 \pm 57.660.087ALT (U/L, mean \pm SD)27.58 \pm 16.1927.97 \pm 16.6826.05 \pm 13.98<0.001	eGFR (mL/min, mean \pm SD)	91.05 ± 27.15	91.48 ± 27.50	89.36 ± 56.70	0.001
ALT (U/L, mean \pm SD)27.58 \pm 16.1927.97 \pm 16.6826.05 \pm 13.98<0.001Potassium (mg/dL, mean \pm SD)4.48 \pm 0.474.48 \pm 0.474.46 \pm 0.490.194Cholesterol (mg/dL, mean \pm SD)183.29 \pm 41.85182.45 \pm 41.69186.56 \pm 42.500.001Triglyceride (mg/dL, mean \pm SD)190.13 \pm 148.40190.5 \pm 143.81188.26 \pm 165.300.559Low-density lipoprotein (mg/dL, mean \pm SD)104.89 \pm 33.93104.37 \pm 33.67106.97 \pm 34.790.002High-density lipoprotein (mg/dL, mean \pm SD)0.91 \pm 0.230.91 \pm 0.230.91 \pm 0.230.91 \pm 0.230.91 \pm 0.23Serum creatinine (mg/dL, mean \pm SD)10.27 \pm 36.609.77 \pm 34.7512.23 \pm 42.080.017Urinary albumin (mg/dL, mean \pm SD)10.27 \pm 36.609.77 \pm 34.7512.23 \pm 42.080.017Urinary creatinine (mg/dL, mean \pm SD)10.27 \pm 36.609.77 \pm 34.7512.23 \pm 42.080.017Urinary creatinine (mg/dL, mean \pm SD)124.41 \pm 66.25123.10 \pm 65.16129.54 \pm 70.14<0.001	FPG (mg/dL, mean \pm SD)	175.19 ± 56.18	174.7 ± 55.79	177.12 ± 57.66	0.087
Potassium (mg/dL, mean \pm SD) 4.48 ± 0.47 4.48 ± 0.47 4.48 ± 0.47 4.46 ± 0.49 0.194 Cholesterol (mg/dL, mean \pm SD) 183.29 ± 41.85 182.45 ± 41.69 186.56 ± 42.50 0.001 Triglyceride (mg/dL, mean \pm SD) 190.13 ± 148.40 190.5 ± 143.81 188.26 ± 165.30 0.599 Low-density lipoprotein (mg/dL, mean \pm SD) 104.89 ± 33.93 104.37 ± 33.67 106.97 ± 34.79 0.002 High-density lipoprotein (mg/dL, mean \pm SD) 0.91 ± 0.23 0.91 ± 0.23 0.91 ± 0.24 0.883 Urinary albumin (mg/dL, mean \pm SD) 10.27 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 124.41 ± 66.25 123.10 ± 65.16 129.54 ± 70.14 <0.001 Metications no. (%)Insulin $3,581$ (34.94%) $2,816$ (34.46%) 765 (36.81%) 0.045 Metformin $6,553$ (63.94%) $5,277$ (64.58%) $1,276$ (61.41%) 0.007 ACE/ARB $7,100$ (69.28%) $5,662$ (69.29%) $1,438$ (69.20%) 0.935 Statin $6,499$ (63.41%) $5,238$ (64.10%) $1,261$ (60.68%) 0.004 Aspirin $5,579$ (54.43%) $4,456$ (54.53%) $1,123$ (54.04%) 0.688 MMSE score (mean \pm SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 Al-cause mortality $1,958$ (19.10%) $1,475$ (18.05%) 483 (23.24%) <0.001	ALT (U/L, mean \pm SD)	27.58 ± 16.19	27.97 ± 16.68	26.05 ± 13.98	<0.001
Cholesterol (mg/dL, mean \pm SD)183.29 \pm 41.85182.45 \pm 41.69186.56 \pm 42.500.001Triglyceride (mg/dL, mean \pm SD)190.13 \pm 148.40190.5 \pm 143.81188.26 \pm 165.300.559Low-density lipoprotein (mg/dL, mean \pm SD)104.89 \pm 33.93104.37 \pm 33.67106.97 \pm 34.790.002High-density lipoprotein (mg/dL, mean \pm SD)41.86 \pm 11.6241.41 \pm 11.2543.63 \pm 12.79<0.001	Potassium (mg/dL, mean \pm SD)	4.48 ± 0.47	4.48 ± 0.47	4.46 ± 0.49	0.194
Triglyceride (mg/dL, mean \pm SD)190.13 \pm 148.40190.5 \pm 143.81188.26 \pm 165.300.559Low-density lipoprotein (mg/dL, mean \pm SD)104.89 \pm 33.93104.37 \pm 33.67106.97 \pm 34.790.002High-density lipoprotein (mg/dL, mean \pm SD)41.86 \pm 11.6241.41 \pm 11.2543.63 \pm 12.79<0.001	Cholesterol (mg/dL, mean \pm SD)	183.29 ± 41.85	182.45 ± 41.69	186.56 ± 42.50	0.001
Low-density lipoprotein (mg/dL, mean \pm SD)104.89 \pm 33.93104.37 \pm 33.67106.97 \pm 34.790.002High-density lipoprotein (mg/dL, mean \pm SD)41.86 \pm 11.6241.41 \pm 11.2543.63 \pm 12.79<0.001	Triglyceride (mg/dL, mean \pm SD)	190.13 ± 148.40	190.5 ± 143.81	188.26 ± 165.30	0.559
High-density lipoprotein (mg/dL, mean \pm SD) 41.86 ± 11.62 41.41 ± 11.25 43.63 ± 12.79 <0.001 Serum creatinine (mg/dL, mean \pm SD) 0.91 ± 0.23 0.91 ± 0.23 0.91 ± 0.23 0.91 ± 0.24 0.883 Urinary albumin (mg/dL, mean \pm SD) 10.27 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 124.41 ± 66.25 123.10 ± 65.16 129.54 ± 70.14 <0.001 Medications no. (%) 1 1 124.41 ± 66.25 $2,816 (34.46\%)$ $765 (36.81\%)$ 0.045 Metformin $6,553 (63.94\%)$ $5,277 (64.58\%)$ $1,276 (61.41\%)$ 0.007 ACEI/ARB $7,100 (69.28\%)$ $5,622 (69.29\%)$ $1,438 (69.20\%)$ 0.935 Statin $6,499 (63.41\%)$ $5,238 (64.10\%)$ $1,261 (60.68\%)$ 0.004 Appirin $5,579 (54.43\%)$ $4,456 (54.53\%)$ $1,123 (54.04\%)$ 0.688 MMSE score (mean \pm SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality $1,958 (19.10\%)$ $1,475 (18.05\%)$ $483 (23.24\%)$ <0.001	Low-density lipoprotein (mg/dL, mean \pm SD)	104.89 ± 33.93	104.37 ± 33.67	106.97 ± 34.79	0.002
Serum creatinine (mg/dL, mean \pm SD) 0.91 ± 0.23 0.91 ± 0.23 0.91 ± 0.24 0.883 Urinary albumin (mg/dL, mean \pm SD) 10.27 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 124.41 ± 66.25 123.10 ± 65.16 129.54 ± 70.14 <0.001 Medications no. (%)Insulin $3,581$ (34.94%) $2,816$ (34.46%) 765 (36.81%) 0.045 Metformin $6,553$ (63.94%) $5,277$ (64.58%) $1,276$ (61.41%) 0.007 ACEI/ARB $7,100$ (69.28%) $5,662$ (69.29%) $1,438$ (69.20%) 0.935 Statin $6,499$ (63.41%) $5,238$ (64.10%) $1,261$ (60.68%) 0.004 Aspirin $5,579$ (54.43%) $4,456$ (54.53%) $1,123$ (54.04%) 0.688 MMSE score (mean \pm SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality $1,958$ (19.10%) $1,475$ (18.05%) 483 (23.24%) <0.001	High-density lipoprotein (mg/dL, mean \pm SD)	41.86 ± 11.62	41.41 ± 11.25	43.63 ± 12.79	< 0.001
Urinary albumin (mg/dL, mean \pm SD) 10.27 ± 36.60 9.77 ± 34.75 12.23 ± 42.08 0.017 Urinary creatinine (mg/dL, mean \pm SD) 124.41 ± 66.25 123.10 ± 65.16 129.54 ± 70.14 <0.001 Medications no. (%)Insulin $3,581$ (34.94%) $2,816$ (34.46%) 765 (36.81%) 0.045 Metformin $6,553$ (63.94%) $5,277$ (64.58%) $1,276$ (61.41%) 0.007 ACEI/ARB $7,100$ (69.28%) $5,622$ (69.29%) $1,438$ (69.20%) 0.935 Statin $6,499$ (63.41%) $5,238$ (64.10%) $1,261$ (60.68%) 0.004 Aspirin $5,579$ (54.43%) $4,456$ (54.53%) $1,123$ (54.04%) 0.688 MMSE score (mean \pm SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality $1,958$ (19.10%) $1,475$ (18.05%) 483 (23.24%) <0.001	Serum creatinine (mg/dL, mean \pm SD)	0.91 ± 0.23	0.91 ± 0.23	0.91 ± 0.24	0.883
Urinary creatinine (mg/dL, mean \pm SD)124.41 \pm 66.25123.10 \pm 65.16129.54 \pm 70.14<0.001Medications no. (%)Insulin3,581 (34.94%)2,816 (34.46%)765 (36.81%)0.045Metformin6,553 (63.94%)5,277 (64.58%)1,276 (61.41%)0.007ACEI/ARB7,100 (69.28%)5,662 (69.29%)1,438 (69.20%)0.935Statin6,499 (63.41%)5,238 (64.10%)1,261 (60.68%)0.004Aspirin5,579 (54.43%)4,456 (54.53%)1,123 (54.04%)0.688MMSE score (mean \pm SD)27.40 \pm 2.5127.39 \pm 2.5227.44 \pm 2.470.634All-cause mortality1,958 (19.10%)1,475 (18.05%)483 (23.24%)<0.001	Urinary albumin (mg/dL, mean \pm SD)	10.27 ± 36.60	9.77 ± 34.75	12.23 ± 42.08	0.017
Medications no. (%) Insulin 3,581 (34.94%) 2,816 (34.46%) 765 (36.81%) 0.045 Metformin 6,553 (63.94%) 5,277 (64.58%) 1,276 (61.41%) 0.007 ACEI/ARB 7,100 (69.28%) 5,662 (69.29%) 1,438 (69.20%) 0.935 Statin 6,499 (63.41%) 5,238 (64.10%) 1,261 (60.68%) 0.004 Aspirin 5,579 (54.43%) 4,456 (54.53%) 1,123 (54.04%) 0.688 MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	Urinary creatinine (mg/dL, mean \pm SD)	124.41 ± 66.25	123.10 ± 65.16	129.54 ± 70.14	< 0.001
Insulin 3,581 (34.94%) 2,816 (34.46%) 765 (36.81%) 0.045 Metformin 6,553 (63.94%) 5,277 (64.58%) 1,276 (61.41%) 0.007 ACEL/ARB 7,100 (69.28%) 5,662 (69.29%) 1,438 (69.20%) 0.935 Statin 6,499 (63.41%) 5,238 (64.10%) 1,261 (60.68%) 0.004 Aspirin 5,579 (54.43%) 4,456 (54.53%) 1,123 (54.04%) 0.688 MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	Medications no. (%)				
Metformin 6,553 (63.94%) 5,277 (64.58%) 1,276 (61.41%) 0.007 ACEI/ARB 7,100 (69.28%) 5,662 (69.29%) 1,438 (69.20%) 0.935 Statin 6,499 (63.41%) 5,238 (64.10%) 1,261 (60.68%) 0.004 Aspirin 5,579 (54.43%) 4,456 (54.53%) 1,123 (54.04%) 0.688 MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	Insulin	3,581 (34.94%)	2,816 (34.46%)	765 (36.81%)	0.045
ACEI/ARB 7,100 (69.28%) 5,662 (69.29%) 1,438 (69.20%) 0.935 Statin 6,499 (63.41%) 5,238 (64.10%) 1,261 (60.68%) 0.004 Aspirin 5,579 (54.43%) 4,456 (54.53%) 1,123 (54.04%) 0.688 MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	Metformin	6,553 (63.94%)	5,277 (64.58%)	1,276 (61.41%)	0.007
Statin 6,499 (63.41%) 5,238 (64.10%) 1,261 (60.68%) 0.004 Aspirin 5,579 (54.43%) 4,456 (54.53%) 1,123 (54.04%) 0.688 MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	ACEI/ARB	7,100 (69.28%)	5,662 (69.29%)	1,438 (69.20%)	0.935
Aspirin 5,579 (54.43%) 4,456 (54.53%) 1,123 (54.04%) 0.688 MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	Statin	6,499 (63.41%)	5,238 (64.10%)	1,261 (60.68%)	0.004
MMSE score (mean ± SD) 27.40 ± 2.51 27.39 ± 2.52 27.44 ± 2.47 0.634 All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	Aspirin	5,579 (54.43%)	4,456 (54.53%)	1,123 (54.04%)	0.688
All-cause mortality 1,958 (19.10%) 1,475 (18.05%) 483 (23.24%) <0.001	MMSE score (mean \pm SD)	27.40 ± 2.51	27.39 ± 2.52	27.44 ± 2.47	0.634
	All-cause mortality	1,958 (19.10%)	1,475 (18.05%)	483 (23.24%)	<0.001

Values are mean ± SD or %. DBP, diastolic blood pressure; SBP, systolic blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; ALT, Alanine aminotransferase; MMSE, mini-mental State Examination; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.

Living Alone Increased Mortality

TABLE 2 | The risk of primary and second outcomes in T2DM Patients with different living status.

Characteristics	Living with others	Living alone	p-value
All-cause mortality			
Cases/n	1,475/8,171	483/2,078	
Unadjusted HR (95% CI)	1.00 (ref)	1.34 (1.20–1.48)	< 0.001
Model 1: adjusted HR (95% CI)	1.00 (ref)	1.31 (1.18–1.46)	< 0.001
Model 2: adjusted HR (95% CI)	1.00 (ref)	1.27 (1.14–1.41)	< 0.001
Model 3: adjusted HR (95% CI)	1.00 (ref)	1.27 (1.14–1.41)	< 0.001
Cardiovascular mortality			
Cases/n	535/8,171	134/2,078	
Unadjusted HR (95% CI)	1.00 (ref)	1.02 (0.84–1.23)	0.858
Model 1: adjusted HR (95% CI)	1.00 (ref)	1.03 (0.85–1.25)	0.782
Model 2: adjusted HR (95% CI)	1.00 (ref)	1.02 (0.83–1.24)	0.871
Model 3: adjusted HR (95% CI)	1.00 (ref)	1.02 (0.83–1.24)	0.881
Non-fatal MI			
Cases/n	738/8,171	198/2,078	
Unadjusted HR (95% CI)	1.00 (ref)	1.09 (0.94–1.28)	0.261
Model 1: adjusted HR (95% CI)	1.00 (ref)	1.13 (0.96–1.33)	0.130
Model 2: adjusted HR (95% CI)	1.00 (ref)	1.08 (0.92–1.27)	0.359
Model 3: adjusted HR (95% CI)	1.00 (ref)	1.08 (0.92–1.27)	0.349
Non-fatal stroke			
Cases/n	374/8,171	114/2,078	
Unadjusted HR (95% CI)	1.00 (ref)	1.26 (1.02–1.56)	0.030
Model 1: adjusted HR (95% CI)	1.00 (ref)	1.25 (1.01–1.55)	0.042
Model 2: adjusted HR (95% CI)	1.00 (ref)	1.18 (0.94–1.46)	0.149
Model 3: adjusted HR (95% CI)	1.00 (ref)	1.18 (0.95–1.47)	0.145
CHF			
Cases/n	549/8,171	147/2,078	
Unadjusted HR (95% CI)	1.00 (ref)	1.14 (0.95–1.36)	0.168
Model 1: adjusted HR (95% CI)	1.00 (ref)	1.10 (0.91–1.33)	0.306
Model 2: adjusted HR (95% CI)	1.00 (ref)	1.08 (0.89–1.30)	0.446
Model 3: adjusted HR (95% CI)	1.00 (ref)	1.07 (0.89–1.30)	0.468
CHD			
Cases/n	1,471/8,171	388/2,078	
Unadjusted HR (95% CI)	1.00 (ref)	1.08 (0.97–1.21)	0.157
Model 1: adjusted HR (95% CI)	1.00 (ref)	1.14 (1.01–1.28)	0.027
Model 2: adjusted HR (95% CI)	1.00 (ref)	1.11 (0.98–1.24)	0.091
Model 3: adjusted HR (95% CI)	1.00 (ref)	1.11 (0.99–1.24)	0.082

Model 1, the following parameters were adjusted: age, sex, previous cardiovascular events, race, BMI, education, SBP, DBP, and smoking status.

Model 2, the following parameters were adjusted: age, sex, previous cardiovascular events, race, education, duration of diabetes, SBP, DBP, smoking status, eGFR, HbA1c, total plasma cholesterol, plasma HDL-C, plasma LDL-C, and depression.

Model 3, the following parameters were adjusted: age, sex, previous cardiovascular events, race, BMI, education, duration of diabetes, depression, SBP, DBP, smoking status, eGFR, HbA1c, total plasma cholesterol, plasma HDL-C, plasma LDL-C, use of statin or biguanide, aspirin, ACEI/ARB, and insulin.

However, the adjusted analysis revealed that living alone was not an independent predictor of non-fatal stroke. These results highlight the clinical importance of living status in individuals with T2DM. The association between living alone and increased risk of all-cause mortality was observed among the prespecified subgroups. This phenomenon could be significant for public health in consideration of the increasing incidence of living alone and how society as a whole and its healthcare systems adapt to this transformation.

The incidence of living alone continues to grow in the general population, and the present study showed that 20.28% of the ACCORD participants were living alone. Living status has been suggested as a risk factor for T2DM. T2DM patients are diverse in terms of ethnicity, life behaviors, socioeconomic status, and psychosocial factors that may play a role in the prognosis of T2DM. Previous studies revealed that the association between living alone and mortality persisted significantly, even after controlling for confounding variables (21). However, few studies have investigated the relationship between living alone and prognosis in patients with T2DM. Hence, it is necessary to evaluate the relationship between living status and adverse events in T2DM patients.

The present study demonstrated that T2DM patients living alone were characterized by older age, higher prevalence of cardiovascular events, higher prevalence of smoking habits, higher BMI, and higher levels of total cholesterol and LDL-C than those living with others. These findings suggest that multifactorial lifestyle modification interventions are likely to be effective in improving the prognosis of T2DM patients living alone. Moreover, our results showed that patients living alone had lower quality of life, suggesting a critical need for adjusting treatment and management strategies to improve the quality of life of these patients.

Our results expanded previous understanding and confirmed that living alone is an independent risk factor for the prognosis of T2DM patients in a long-term follow-up. However, the potential mechanisms underlying such association are unclear, several factors have been found to be associated with mortality. Several studies have found that individuals living alone have worse self-perceived health and quality of life, depression, and feelings of loneliness (22-24). Consistent with previous reports, our study further confirmed that T2DM patients living alone experienced more feelings of depression (25.71% vs. 21.99%, P <0.001). Moreover, numerous studies have shown that depression is associated with a higher mortality rate (25). Katon et al. conducted a study on 4,000 patients with T2DM. Over a 3year follow-up, the mortality in patients with mild or severe depression was 1.7 and 2.3 times higher, respectively, than that of patients without depression (26). Similar findings were reported by Zhang et al. in a survival analysis using the National Health and Nutrition Examination Survey (NHANES)-I data (27).

The majority of studies have also found that living alone is associated with poor diabetes self-care, and especially poor dietary arrangements (28). Dietary patterns are closely related to the optimal management of T2DM in the general population (28–30). The diverse features of people living alone and complex social and demographic changes could influence the dietary patterns of patients with T2DM. All these factors could affect compliance with the guidelines to optimize nutritional status. The relationship between living alone and dietary patterns has also been discussed previously (31, 32). Although a few studies found some healthy behaviors in patients living alone, most studies found that a larger number of patients living alone are



less likely to follow healthy dietary habits, including the intake of diverse foods and the consumption of fruits and vegetables (31, 33). Furthermore, there is a possibility that a decline in motivation and pleasure in cooking and/or eating in people living alone, which often manifests in the cooking of simple meals or the consumption of ready-made food. The likely consequences are difficulty in following healthy eating recommendations and in controlling portion size. Aspects of psychological and mental



health related to living alone could also affect food intake, resulting in increased or decreased dietary intake.

Previous studies have found that T2DM patients living alone show poor medication adherence, including to prescribed

medications and blood measurements. Strict glycemic management is associated with a decreased risk of diabetesrelated complications, especially in individuals who have not suffered years of uncontrolled HbA1c levels (34). Projections

from the observational United Kingdom Prospective Diabetes Research (UKPDS 35) proposed that a 1 percent decrease in mean HbA1c would lead to a 14% lower risk of all-cause mortality, 21% lower rate of diabetes-related mortality, and 37% decline in the risk of microvascular complications (35). Spencer et al. suggested that education and support from peers allow T2DM patients to achieve better self-management in the long term, leading to good efficacy of HbA1c control (36). A link between living alone and worse HbA1c management has also been observed in a recent study (37). Our results are consistent with those previous findings, as the mean HbA1c level in T2DM patients living alone in our study was higher than that in patients living with one or more adults. We also found that the risk of CHF and CHD was significantly higher in individuals living alone among propensity score-matched patients. Recent research has described the association between living alone and the incidence of adverse cardiovascular events (35, 38). The Coronary Revascularization Demonstrating Outcome Study in Kyoto of Acute Myocardial Infarction Registry (CREDO—Kyoto AMI) showed that, in a 5-year follow-up, individuals living alone had higher risk of admission for HF (39). The Reduction of Atherothrombosis for Continued Health (REACH) study also showed that living alone was associated with a higher risk of mortality and CV death (40). A possible explanation is that living alone may increase anxiety and depression, causing more psychological distress,





8

poor handling mechanisms and self-care, less access to healthcare services, and less insistence on guideline-recommended therapy and secondary prevention targets.

LIMITATIONS

The first limitation of this study is that it was a post-hoc, exploratory analysis of the ACCORD data; randomization may break, and residual and uncontrolled confounding may still be present. Additionally, the data included in the present study, derived from clinical trials, may not be representative of realworld populations of patients with T2DM. Third, we were unable to account or adjust for unidentified confounders, such as stress and socioeconomic status. Unfortunately, although the statistical modeling included multiple factors, including psychosocial factors and medical history, we acknowledge that there remains a potential for residual confounding. Fourth, living alone was assessed only once at baseline: we did not re-evaluate the living status during follow-up, during which cohabitation status or social circumstances may have changed. Information from prospective clinical trials is needed to clarify the practical effects of living alone in patients with T2DM.

CONCLUSION

The present study suggests that living status may be a strong marker for predicting the prognosis of T2DM patients, an observation which warrants confirmation in further studies. The main significance of the present study was the identification of specific high-risk factors affecting the prognosis of T2DM. Therefore, these findings have potential implications for public health. Society as a whole needs to be prepared to the negative effects of the increasing rate of individuals living alone.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. The datasets are available from the ACCORD/ACCORDIN Research

REFERENCES

- Rico-Uribe LA, Caballero FF, Martin-Maria N, Cabello M, Ayuso-Mateos JL. M. Miret Association of loneliness with all-cause mortality: a meta-analysis. *PLoS ONE.* (2018) 13:e0190033. doi: 10.1371/journal.pone.0190033
- Pantell M, Rehkopf D, Jutte D, Syme SL, Balmes JN. Adler Social isolation: a predictor of mortality comparable to traditional clinical risk factors. *Am J Public Health.* (2013) 103:2056–62. doi: 10.2105/AJPH.2013.3 01261
- Tomassini C, Glaser K, Wolf DA. Broese van Groenou MI, Grundy E. Living arrangements among older people: an overview of trends in Europe and the USA. *Popul Trends*. (2004) 115:24–34.
- Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. *PLoS Med.* (2010) 7:e1000316. doi: 10.1371/journal.pmed.1000316
- Shankar A, McMunn A, Banks J, Steptoe A. Loneliness, social isolation, behavioral and biological health indicators in older adults. *Health Psychol.* (2011) 30:377–85. doi: 10.1037/a0022826

Materials obtained from the National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Second Xiangya Hospital of Central South University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

This study was completed in collaboration with the following authors: YW and ST defined the study theme and methods. LF, YZ, and JS analyzed the data. LF wrote the paper. ZX and ST edited the paper. All authors have read and approved the final manuscript.

FUNDING

This research was supported by the National Natural Science Foundation of China (81801394 to ST) and the Natural Science Foundation of Hunan Province (2019JJ50878 to ST).

ACKNOWLEDGMENTS

We thank the Core Facility at the National Clinical Research Center for Metabolic Diseases for interpretation of results.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed. 2022.782751/full#supplementary-material

- Nicholson NR. A review of social isolation: an important but underassessed condition in older adults. J Prim Prev. (2012) 33:137–52. doi: 10.1007/s10935-012-0271-2
- Shaw BA, Dahlberg L, Nilsen C, Agahi N. Trends in the mortality risk of living alone during old age in Sweden, 1992–2011. J Aging Health. (2020) 32:1399–408. doi: 10.1177/0898264320930452
- Gopinath B, Rochtchina E, Anstey KJ, Mitchell P. Living alone and risk of mortality in older, community-dwelling adults. *JAMA Intern Med.* (2013) 173:320–1. doi: 10.1001/jamainternmed.2013.1597
- Stickley A, Koyanagi A, Roberts B, Richardson E, Abbott P, Tumanov S, McKee M. Loneliness: its correlates and association with health behaviours and outcomes in nine countries of the former Soviet Union. *PLoS ONE*. (2013) 8:e67978. doi: 10.1371/journal.pone.0067978
- Vlachantoni A, Shaw RJ, Evandrou M, Falkingham J. The determinants of receiving social care in later life in England. *Ageing Soc.* (2015) 35:321– 45. doi: 10.1017/S0144686X1300072X
- 11. Lammintausta A, Airaksinen JK, Immonen-Raiha P, Torppa J, Kesaniemi AY, Ketonen M, et al. Prognosis of acute coronary events is worse in patients living

alone: the FINAMI myocardial infarction register. *Eur J Prev Cardiol*. (2014) 21:989–96. doi: 10.1177/2047487313475893

- Schmaltz HN, Southern D, Ghali WA, Jelinski SE, Parsons GA, King KM, Maxwell CJ. Living alone, patient sex and mortality after acute myocardial infarction. J Gen Intern Med. (2007) 22:572–8. doi: 10.1007/s11606-007-0106-7
- Zhaowei Z, Xiaofan P, Hebin X, Cuihong T, Haoran X, Qinna L, et al. Comparison of one-year survival after acute coronary syndrome in patients >/=75 years of age with versus without living with spouse. *Am J Cardiol.* (2019) 123:1–6. doi: 10.1016/j.amjcard.2018.09.032
- A. American Diabetes. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. *Diabetes Care*. (2021) 44:S125– 50. doi: 10.2337/dc21-S010
- Nam GE, Kim W, Han K, Jung JH, Han, Kim J, et al. Association between living alone and incident type 2 diabetes among middleaged individuals in Korea: a nationwide cohort study. *Sci Rep.* (2021) 11:3659. doi: 10.1038/s41598-021-82868-z
- Hilding A, Shen C, Ostenson CG. Social network and development of prediabetes and type 2 diabetes in middle-aged Swedish women and men. *Diabetes Res Clin Pract.* (2015) 107:166–77. doi: 10.1016/j.diabres.2014. 09.057
- Meisinger A, Kandler U, Ladwig KH. Living alone is associated with an increased risk of type 2 diabetes mellitus in men but not women from the general population: the MONICA/KORA Augsburg Cohort Study. *Psychosom Med.* (2009) 71:784–8. doi: 10.1097/PSY.0b013e3181a e5770
- Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. (2008) 358:2545– 59. doi: 10.1056/NEJMoa0802743
- ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. *Diabetes Care*. (2016) 39:701– 8. doi: 10.2337/dc15-2283
- ACCORD Study, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. *Am J Cardiol.* (2007) 99:21i–33i.
- Ng N, Santosa A, Weinehall L, Malmberg G. Living alone and mortality among older people in Vasterbotten County in Sweden: a survey and register-based longitudinal study. BMC Geriatr. (2020) 20:7. doi: 10.1186/s12877-019-1330-9
- Joutsenniemi K, Martelin T, Martikainen P, Pirkola S, Koskinen S. Living arrangements and mental health in Finland. J Epidemiol Community Health. (2006) 60:468–75. doi: 10.1136/jech.2005. 040741
- Sok SR, Yun EK. A comparison of physical health status, self-esteem, family support and health-promoting behaviours between aged living alone and living with family in Korea. J Clin Nurs. (2011) 20:1606– 12. doi: 10.1111/j.1365-2702.2010.03551.x
- Pulkki-Raback L, Kivimaki M, Ahola K, Joutsenniemi K, Elovainio M, Rossi H. et al. Living alone and antidepressant medication use: a prospective study in a working-age population. *BMC Public Health*. (2012) 12:236. doi: 10.1186/1471-2458-12-236
- Goins RT, Noonan C, Winchester B, Brock D. Depressive symptoms and allcause mortality in older american indians with type 2 diabetes mellitus. J Am Geriatr Soc. (2019) 67:1940–5. doi: 10.1111/jgs.16108
- Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. *Diabetes Care*. (2005) 28:2668–72. doi: 10.2337/diacare.28.11.2668
- Zhang X, Norris SL, Gregg EW, Cheng YJ, Beckles G, Kahn HS. Depressive symptoms and mortality among persons with and without diabetes. *Am J Epidemiol.* (2005) 161:652–60. doi: 10.1093/aje/kwi089
- Schoenaker DA, Mishra GD, Callaway LK, Soedamah-Muthu SS. The role of energy, nutrients, foods, dietary patterns in the development of gestational diabetes mellitus: a systematic review of observational studies. *Diabetes Care*. (2016) 39:16–23. doi: 10.2337/dc15-0540

- Archundia Herrera MC, Subhan FB, Chan CB. Dietary patterns and cardiovascular disease risk in people with type 2 diabetes. *Curr Obes Rep.* (2017) 6:405–13. doi: 10.1007/s13679-017-0284-5
- Papamichou D, Panagiotakos DB, Itsiopoulos C. Dietary patterns and management of type 2 diabetes: a systematic review of randomised clinical trials. *Nutr Metab Cardiovasc Dis.* (2019) 29:531–43. doi: 10.1016/j.numecd.2019.02.004
- Sellaeg K, Chapman GE. Masculinity and food ideals of men who live alone. *Appetite*. (2008) 51:120–8. doi: 10.1016/j.appet.2008.01.003
- Davis MA, Murphy SP, Neuhaus JM, Gee L, Quiroga SS. Living arrangements affect dietary quality for U.S. adults aged 50 years and older: NHANES III 1988–1994. J Nutr. (2000) 130:2256–64. doi: 10.1093/jn/130.9.2256
- Quandt SA, McDonald J, Arcury TA, Bell RA, Vitolins MZ. Nutritional selfmanagement of elderly widows in rural communities. *Gerontologist.* (2000) 40:86–96. doi: 10.1093/geront/40.1.86
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year followup of intensive glucose control in type 2 diabetes. N Engl J Med. (2008) 359:1577–89. doi: 10.1056/NEJMoa0806470
- Jensen MT, Marott JL, Holtermann A, Gyntelberg F. Living alone is associated with all-cause and cardiovascular mortality: 32 years of follow-up in the Copenhagen Male Study. *Eur Heart J Qual Care Clin Outcomes.* (2019) 5:208–17. doi: 10.1093/ehjqcco/qcz004
- 36. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. (2000) 321:405–12. doi: 10.1136/bmj.321.7258.405
- 37. Sakai R, Hashimoto Y, Hamaguchi M, Ushigome E, Okamura t, Majima s, et al. Living alone is associated with visit-to-visit HbA1c variability in men but not in women in people with type 2 diabetes: KAMOGAWA-DM cohort study. *Endocr J*. (2020) 67:419–26. doi: 10.1507/endocrj.EJ19-0436
- Gandhi S, Goodman SG, Greenlaw N, Ford I, McSkimming P, Ferrari R. et al. Living alone and cardiovascular disease outcomes. *Heart.* (2019) 105:1087– 95. doi: 10.1136/heartjnl-2018-313844
- 39. Nakatsuma K, Shiomi H, Watanabe H, Morimoto T, Taniguchi T, Toyota T. et al. Comparison of long-term mortality after acute myocardial infarction treated by percutaneous coronary intervention in patients living alone versus not living alone at the time of hospitalization. *Am J Cardiol.* (2014) 114:522– 7. doi: 10.1016/j.amjcard.2014.05.029
- Udell JA, Steg PG, Scirica BM, Smith SC, Ohman EM, Eagle KA, et al. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. *Arch Intern Med.* (2012) 172:1086–95. doi: 10.1001/archinternmed.2012.2782

Author Disclaimer: The contents of this report do not necessarily reflect the opinions or views of the ACCORD/ACCORDIN study authors or the NHLBI.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fu, Zhou, Sun, Xing, Wang and Tai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.